Description: Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its product pipeline focuses on the intracellular access by various types of vaccine and by protein-delivery system, such as monoclonal antibody-based therapies. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Home Page: defencetherapeutics.com
1680 – 200 Burrard Street
Vancouver,
BC
V6C 3L6
Canada
Phone:
514 947 2272
Officers
| Name | Title |
|---|---|
| Mr. Sebastien Plouffe | CEO, President & Director |
| Mr. Patrick Joseph Meagher C.A., CPA, CA, CPA | Chief Financial Officer |
| Dr. Maxime Parisotto | Chief Scientific Officer & Director of Science and Business Development |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 91.1146 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |